Sheet 05 / Frequently Asked Questions
Questions, Answered From the Record.
Ten questions readers ask most about KLOW, answered from the cited literature. None of these answers is medical advice.
What is the KLOW peptide blend?
KLOW is a vendor-coined acronym for a four-peptide research formulation supplied as a single lyophilized vial. Across the major research-chemical suppliers, the dominant composition is GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, eighty milligrams total, mass-ratio 50:10:10:10 [6][4][10][14]. It is a research-only blend. No component is FDA-approved for any indication. No combination study has been published.
What peptides are in KLOW and in what ratio?
The four components and their mass shares in the canonical 80 mg vial are: GHK-Cu at 50 mg (a copper-binding tripeptide, MW 340.4 / 403.9 with copper) [6]; BPC-157 at 10 mg (a 15-amino-acid pentadecapeptide, MW 1419.5) [4]; TB-500 at 10 mg (synthetic thymosin beta-4, a 44-amino-acid peptide, MW 4963) [10]; and KPV at 10 mg (the C-terminal tripeptide of alpha-MSH, MW 342.4) [14]. The mass ratio is 50:10:10:10.
How does each component of KLOW work?
Four different pathways. GHK-Cu modulates gene expression and drives matrix remodeling, fibroblast activation, and collagen/elastin/glycosaminoglycan synthesis; a Connectivity Map analysis showed GHK reverted a 127-gene COPD-severity signature toward the healthy baseline [6][8]. BPC-157 activates VEGFR2 internalization and the Akt-eNOS angiogenic pathway and modulates vasomotor tone via Src-Caveolin-1-eNOS signaling [2][3]. TB-500 sequesters G-actin via its LKKTET binding motif, regulating cytoskeletal dynamics for cell migration and reducing scar formation [10][11]. KPV is taken into cells via PepT1 and suppresses NF-kB activation, lowering TNF-alpha, IL-1-beta, and IL-6 output in inflamed tissue [14][16]. The four mechanisms do not overlap.
Is there any published study of the full KLOW blend?
No. No peer-reviewed in-vivo study of GHK-Cu + BPC-157 + TB-500 + KPV co-administered at any ratio has been published in humans or animals. All efficacy data is monotherapy-only. The combination rationale — that the four peptides cover non-overlapping aspects of tissue repair and inflammation — is mechanistic extrapolation from individual-component data, not direct evidence. No pharmacokinetic profile exists for a KLOW-style four-peptide formulation, so plasma stability under co-administration, pharmacokinetic interactions, and tissue distribution under fixed-ratio dosing are uncharacterized.
What does the research say about GHK-Cu, BPC-157, TB-500, and KPV individually?
Component literatures vary in depth. BPC-157 has the largest preclinical base — a 2025 HSS Journal systematic review screened 544 articles and included 36, of which 35 were preclinical [19]. TB-500 has the most human data, including Phase 1 IV safety (42 mg to 1260 mg single doses), a Phase 3 ophthalmic trial that met its US endpoint (RGN-259 in neurotrophic keratopathy), and a 2025 cardiac trial reporting reduced infarct size and improved LV function in STEMI patients receiving IV thymosin beta-4 within 12 hours of PCI [12][13][18]. GHK-Cu has small dermatologic studies, hair-follicle organ-culture work, and a deep mechanistic literature on gene expression [6][8][9]. KPV has rodent colitis evidence — Dalmasso 2008 documented approximately 50% reduction in colon inflammation markers at 100 micromolar oral [14] — and no published human trial. KPV is scheduled for FDA Pharmacy Compounding Advisory Committee review in mid-2026.
What is the regulatory status of the KLOW blend and its components?
None of the four components holds FDA approval for any indication. BPC-157 was placed in FDA Category 2 of the 503A Interim Bulks Guidance in September 2023, halting compounding-pharmacy production; it was removed from Category 2 in April 2026 after nominators withdrew nominations, but it remains an unapproved drug substance. KPV is scheduled for FDA Pharmacy Compounding Advisory Committee review in mid-2026. GHK-Cu is used in cosmetic formulations but has no drug approval. TB-500 (synthetic thymosin beta-4) has no FDA-approved drug form, though RGN-259 (ophthalmic thymosin beta-4) has been the subject of Phase 2 and Phase 3 trials. There is no European Medicines Agency approval for any component or for the blend itself.
Are KLOW peptides on the WADA prohibited list?
BPC-157 and TB-500 are both prohibited under WADA category S0 (Non-Approved Substances), banned at all times in and out of competition for athletes. KPV and GHK-Cu are not explicitly listed by WADA, but any non-approved pharmacological substance is captured by S0 in principle. The KLOW blend, by including BPC-157 and TB-500, is on its face a prohibited preparation for any competitive athlete subject to WADA enforcement.
What is the difference between KLOW and Wolverine blend?
KLOW is the four-component blend (GHK-Cu + BPC-157 + TB-500 + KPV). Wolverine, in most current research-chemical supplier listings, is a two-component blend of BPC-157 + TB-500. There is documented overlap in some early hobbyist sources — a Wolverine variant has been described that adds GHK-Cu and KPV, partially mirroring KLOW — but the dominant commercial composition for the two named blends is four-component KLOW versus two-component Wolverine. Neither blend has been studied as a fixed-ratio combination in peer-reviewed in-vivo research.
What human clinical data exists for any component of KLOW?
Component by component: BPC-157 has one Phase II ulcerative colitis trial (PL 14736 enema, Pliva, Croatia) whose results were never published in peer-reviewed literature [5], plus a single 12-patient retrospective case series identified in the 2025 HSS systematic review [19]. TB-500 has Phase 1 IV safety data in healthy volunteers [12], a US Phase 3 trial in neurotrophic keratopathy that met its primary endpoint [13], a European Phase 3 in neurotrophic keratitis that missed its primary endpoint, and a 2025 Phase 1/2 cardiac trial in STEMI [18]. GHK-Cu has small dermatologic and cosmetic studies but no large pivotal trials. KPV has no published human clinical trial data.
What are common research-only routes and doses for the KLOW components?
Documented in the published research literature: BPC-157 at 10 ug/kg intraperitoneal once daily in rodent musculoskeletal models [1][4]; GHK-Cu at 0.01-0.05% topical in human-skin studies [6]; thymosin beta-4 at 0.01-0.03% topical for dermal trials, 0.1% solution for the ophthalmic Phase 3 (RGN-259), 42 to 1260 mg single IV doses in Phase 1 systemic safety [10][12][13]; KPV at 100 micromolar in drinking water for murine colitis studies [14]. These are research-context doses from the published literature. No standardized research dose exists for the four-peptide blend, and no doses on this site are recommendations for human use.
Why does this site exist if the combination has not been studied?
Because the literature gap is itself the most important fact about the blend, and the per-component literatures are large enough to be worth aggregating in one place. Readers searching 'KLOW' should find an accurate inventory of what has been studied (the four monotherapy literatures), what has not been studied (any in-vivo combination, any blend pharmacokinetics, any human KLOW trial), and the regulatory status of each piece. The site exists to publish that record, not to sell, recommend, or administer anything.
Does KLOW Meds sell peptides or provide treatment?
No. KLOW Meds does not sell any peptide, does not provide treatment, does not employ clinicians, and is not a pharmacy or compounder. The 'meds' modifier in the domain is editorial framing — the position the publisher occupies relative to the literature, not a claim about the site's services. Read the /about page for the full publisher statement.